Abstract 3698
Background
Patient-centered endpoints, overall survival (OS) and QoL (where the benefit is detectable by the patient as an improvement in symptoms or functional capacity), are considered valid “direct” endpoints by the FDA. While EORTC-C30 is an accepted indicator of QoL, there is no accepted standard for time to QoL status improvement, nor any accepted standard of analysis for EORTC-C30 data.
Methods
A single-group, open-label, feasibility study was performed to assess QoL status in HCC patients exposed to modulated EMF at patient-specific frequencies. A 120-min outpatient EMF exposure procedure was performed every 30 days until significant QoL deterioration or death. An oral spoon-shaped RF antenna applicator was used to apply EMF while individuals were kept in supine position. EORTC-C30 v3.0 questionnaires were answered by individuals immediately prior to every EMF exposure. The 17 QoL parameters were divided into those measuring improvement (G+ functional scales and global health status/QOL) and those measuring deterioration (G- symptom scales). QoL index was calculated as (mean G+) – (mean G-). Different QoL index calculations were made using three groups of QoL parameters: all 17 QoL parameters, 15 QoL parameters (removing Functional scales and Symptom scales) and 3 QoL parameters (restricted to Functional scales, Symptom scales and Global health status/QOL). A change of +/-5% in QoL index was considered a clinically relevant improvement/deterioration in QoL status.
Results
42 HCC were exposed to 151 EMF procedures. 4,530 QoL data points were collected for analysis, with 0.1% missing data. QoL index was measured at baseline and 30 days after the baseline exposure procedure. Using the 3 QoL index calculation methods (17 QoL, 15 QoL and 3 QoL) measured 30 days from the baseline exposure, QoL status improved in 63%, 59% and 74% of HCC patients respectively.
Conclusions
Rapid and significant improvement in QoL status in HCC patients exposed to EMF was detected within 30 days of exposure regardless of the QoL index calculation methods used.
Clinical trial identification
NCT 01686412.
Editorial acknowledgement
Luiz Fernando Reis PhD, Research Director Hospital Sírio Libanês, São Paulo, Brazil, Riad Younes MD and Bertram Wiedenmann PhD MD.
Legal entity responsible for the study
Hospital Sírio Libanês.
Funding
Has not received any funding.
Disclosure
F.P. Costa: Leadership role: Autem Medical. A. Iemma: Honoraria (institution): Autem Medical. F. Soares: Honoraria (institution): Autem Medical. J. Tuszynski: Advisory / Consultancy: Autem Medical. All other authors have declared no conflicts of interest.
Resources from the same session
5011 - LCSCAF1 maintains cancer stem-like traits by stabilizing c-Myc protein and promotes metastasis and recurrence in lung cancer
Presenter: Tao Guo
Session: Poster Display session 1
Resources:
Abstract
4955 - XAF1 Enhances Temozolomide Induced Autophagic Cell Death through AMPK signaling pathway
Presenter: Mingoo Lee
Session: Poster Display session 1
Resources:
Abstract
5616 - The effect of cortisol on methylation patterns in breast cancer cell lines
Presenter: Haya Intabli
Session: Poster Display session 1
Resources:
Abstract
4649 - Global and sex-specific epigenome-wide association studies for the identification of the main methylated loci related to smoking in a Mediterranean population
Presenter: Judith Begona Ramirez Sabio
Session: Poster Display session 1
Resources:
Abstract
4984 - Whole transcriptomics analyses of mimicking Circulating Tumor Cells (CTCs) by single-cell RNA sequencing (scRNAseq)
Presenter: Jessica Garcia
Session: Poster Display session 1
Resources:
Abstract
5926 - Comparison of enzymatic- and bisulfite conversion to map the plasma cell-free methylome in cancer
Presenter: Nicole Lambert
Session: Poster Display session 1
Resources:
Abstract
5454 - Detection of low mutations in hepatocellular carcinoma by using circulating tumor DNA
Presenter: Esl Kim
Session: Poster Display session 1
Resources:
Abstract
4428 - Variants in the JAK1 and JAK2 genes in the risk and prognosis of patients with cutaneous melanoma
Presenter: Bruna Carvalho
Session: Poster Display session 1
Resources:
Abstract
4409 - P-Rex1 expression in breast cancer patients.
Presenter: Angela Lara Montero
Session: Poster Display session 1
Resources:
Abstract
4185 - Modulation of Risk of Cutaneous Melanoma Patients by Variants in STAT3 Gene and Functional Analysis
Presenter: Gabriela Gomez
Session: Poster Display session 1
Resources:
Abstract